Baseline characteristics were generally well balanced between the groups, except for the proportion of patients with a PD-L1 tumor proportion score of 1% or higher (16 [28.1%] of 57 patients in the ICI Plus Chemo group vs. 13 [13.3%] of 98 patients in the Chemo group) and the percentage of patients who were administered bevacizumab intravenously (0 of 57 patients in the ICI Plus Chemo group vs. 18 [18.4%] of 98 patients in the Chemo group) (Table 1). The gene discussed is CD274; the disease is neoplasm.